DEEJ(000423) ZHESHANG SECURITIES·2024-10-09 14:23Investment Rating - The investment rating for the company is maintained at "Buy" [2][4]. Core Views - The company is expected to achieve a net profit attributable to shareholders of 1.1 to 1.175 billion yuan for the first three quarters of 2024, representing a year-on-year growth of 40% to 50%, with a midpoint of 1.138 billion yuan, which is a 45% increase [1]. - The company is focused on a "growth and quality" development theme for 2024, emphasizing the creation of new production capabilities and enhancing brand influence through integrated marketing and digital investment [1]. - The company aims to become the most trusted health supplement leader, leveraging its "1238" strategy to solidify its brand position and expand its dual-driven growth model of pharmaceuticals and health products [1]. Financial Summary - The forecasted revenue for 2024 is 5.96 billion yuan, with a year-on-year growth of 26.4% [3]. - The projected net profit for 2024 is 1.459 billion yuan, reflecting a year-on-year increase of 26.76% [3]. - The earnings per share (EPS) for 2024 is estimated at 2.27 yuan, with a price-to-earnings (P/E) ratio of 25.43x [3].